Following admission to the intensive care unit hours ago for status asthmaticus, a 26-year-old woman is evaluated due to new-onset tachypnea. Her initial treatment included continuous albuterol nebulization, intravenous methylprednisolone, and supplemental oxygen. Over the past day, her peak expiratory flow rate has improved significantly from 35% to 70% of her baseline. Auscultation currently demonstrates clear breath sounds bilaterally with minimal end-expiratory wheezing.
Despite this objective improvement in her airway resistance, she reports feeling profoundly anxious and her respiratory rate has climbed to 32/min.
Vital signs are:
| Parameter | Value |
|---|---|
| Temperature | () |
| Blood pressure | 118/74 mm Hg |
| Heart rate | 118/min |
| Respiratory rate | 32/min |
| Oxygen saturation | 98% on room air |
Laboratory studies reveal:
| Test | Result |
|---|---|
| Serum sodium | 142 mEq/L |
| Serum potassium | 3.1 mEq/L |
| Serum chloride | 104 mEq/L |
| Serum bicarbonate | 14 mEq/L |
| Blood urea nitrogen | 12 mg/dL |
| Serum creatinine | 0.7 mg/dL |
An arterial blood gas obtained on room air shows:
| Gas | Value |
|---|---|
| pH | 7.28 |
| PaCO2 | 30 mm Hg |
| PaO2 | 102 mm Hg |
Which of the following is the most likely underlying mechanism for this patient's current clinical deterioration?
- Beta-2 adrenergic receptor hyperstimulationCevap
- BExhaustion of the diaphragmatic musculature
- CExcessive renal excretion of bicarbonate
- DIntrapulmonary mismatch of ventilation and perfusion
- ESystemic inflammatory response to microbial invasion
Cevap
Beta-2 adrenergic receptor hyperstimulation
The correct answer is beta-2 adrenergic receptor hyperstimulation. This patient's ABG demonstrates a primary metabolic acidosis (pH 7.28, low bicarbonate 14 mEq/L) with an appropriately compensated respiratory alkalosis ( 30 mm Hg), as confirmed by Winter's formula. Furthermore, the serum anion gap is markedly elevated at 24. In the clinical setting of severe asthma treated with continuous nebulized albuterol, this triad indicates Type B lactic acidosis. High systemic concentrations of albuterol overstimulate beta-2 receptors in skeletal muscle, profoundly accelerating glycogenolysis and glycolysis. This rapid breakdown produces pyruvate much faster than the mitochondria can process it via the citric acid cycle, leading to the massive accumulation of lactate.
Crucially, her tachypnea is a physiological compensatory response (Kussmaul breathing) attempting to buffer the acidemia, not a sign of worsening bronchospasm, as corroborated by her improving peak expiratory flow rates and clear lung sounds. Concurrent hypokalemia further supports systemic beta-2 hyperstimulation, which drives potassium intracellularly. If clinicians mistakenly interpret this compensatory tachypnea as impending respiratory failure, they may inappropriately administer more albuterol, dangerously worsening the lactic acidosis.
Crucially, her tachypnea is a physiological compensatory response (Kussmaul breathing) attempting to buffer the acidemia, not a sign of worsening bronchospasm, as corroborated by her improving peak expiratory flow rates and clear lung sounds. Concurrent hypokalemia further supports systemic beta-2 hyperstimulation, which drives potassium intracellularly. If clinicians mistakenly interpret this compensatory tachypnea as impending respiratory failure, they may inappropriately administer more albuterol, dangerously worsening the lactic acidosis.
Adım Adım Çözüm
Anahtar Kavram
Type B lactic acidosis is a severe complication of high-dose, continuous beta-2 agonist (albuterol) therapy, presenting as a compensated high anion gap metabolic acidosis with paradoxical tachypnea that must not be confused with worsening asthma.
Tahmini Süre:2m 0s